Ocrelizumab in pediatric patients with MS: Efficacy, tolerability, and safety

Eur J Paediatr Neurol. 2023 Mar:43:A1. doi: 10.1016/j.ejpn.2023.03.003. Epub 2023 Mar 24.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Child
  • Humans
  • Immunologic Factors / adverse effects
  • Multiple Sclerosis* / complications
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting* / drug therapy

Substances

  • ocrelizumab
  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors